Healthcare / BiotechnologyNasdaqCM
$2.73
-0.11 (-3.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.7M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$14M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-243.3%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-13.0M · FCF $-15.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Net Income | $-13.0M | $-13.0M | $-27.6M | $-12.5M | $-14.0M | $-15.3M | $-29.7M | $-21.3M | $-15.5M | $-33.4M | $-14.6M | $-9.0M | $-320000.00 |
| EBITDA | $-13.7M | $-13.7M | $-28.8M | $-15.9M | $-11.8M | — | — | — | — | — | — | — | — |
| EPS | -7.35 | -7.35 | -39.16 | -27.06 | -477.84 | -1743.28 | -4831.20 | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||
| Debt/Equity | 0.04 | 0.04 | 0.02 | 0.01 | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.73 | 2.73 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-15.7M | $-15.7M | $-24.7M | $-10.8M | $-11.7M | $-15.1M | $-10.8M | $-7.3M | $-14.5M | — | — | — | — |
| Returns | |||||||||||||
| ROE | -243.3% | -243.3% | -347.9% | -74.7% | -64.2% | -104.7% | -412.0% | -173.4% | 116.9% | -133660.0% | -70.7% | 72.9% | 60.3% |
| Valuation | |||||||||||||
| P/B | 0.90 | 0.90 | 2.09 | 1.18 | 0.08 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| EPS Growth | 81.2% | 81.2% | -44.7% | 94.3% | — | 63.9% | — | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-39.16 → -7.35
Residual
-61.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.